Advanced Enzyme Technologies Ltd (IN:ADVENZYMES)
:ADVENZYMES
ADVENZYMES Stock Chart & Stats
₹303.25
-₹1.10(-0.32%)
At close: 4:00 PM EST
₹303.25
-₹1.10(-0.32%)
Day’s Range― - ―
52-Week Range₹251.90 - ₹366.55
Previous CloseN/A
Volume535.87K
Average Volume (3M)13.78K
Market Cap
₹30.55B
Enterprise Value₹30.22B
Total Cash (Recent Filing)₹6.19B
Total Debt (Recent Filing)₹346.54M
Price to Earnings (P/E)19.9
Beta1.10
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.7%
Share Statistics
EPS (TTM)2.80
Shares Outstanding111,926,800
10 Day Avg. Volume10,375
30 Day Avg. Volume13,779
Financial Highlights & Ratios
PEG Ratio-13.34
Price to Book (P/B)2.27
Price to Sales (P/S)5.07
P/FCF Ratio28.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.2
Revenue Forecast (FY)₹8.91B
Bulls Say, Bears Say
Bulls Say
Recurring B2B Consumable RevenueEnzymes and probiotics are consumable inputs used continuously in manufacturing across human, animal and food industries. That creates recurring, contract-like demand and customer stickiness, supporting revenue visibility and durable topline stability across cycles and markets.
High Margins With Consistent Revenue GrowthSustained double-digit gross and high net margins indicate product differentiation and pricing power in specialty enzyme markets. Combined with consistent revenue growth, margins provide internal cash for R&D and capacity, supporting long-term competitiveness and margin resilience.
Conservative Balance Sheet And Low LeverageExtremely low leverage and a high equity ratio give the company strong financial flexibility to fund capex, absorb shocks, pursue strategic investments, or expand exports without stressing liquidity, reducing bankruptcy risk and supporting steady operational execution.
Bears Say
Modest Free Cash Flow GrowthWhile operating cash generation and FCF-to-net-income are favorable, the modest pace of FCF growth limits the company’s ability to accelerate capacity expansion, larger M&A or faster return of capital. Over time this can constrain scale-up or strategic flexibility.
Slight Decline In EBIT MarginA falling EBIT margin signals emerging cost or operational efficiency issues. If not addressed, margin erosion could reduce cash available for reinvestment and weaken pricing power versus competitors, making profitability more sensitive to raw-material or energy cost swings.
ROE Below Industry LeadersA mid-single-digit ROE relative to top peers implies capital is not delivering top-tier returns. The conservative capital structure supports safety but may cap shareholder returns unless operational efficiency or higher-growth initiatives lift asset productivity over time.
Advanced Enzyme Technologies Ltd News
ADVENZYMES FAQ
What was Advanced Enzyme Technologies Ltd’s price range in the past 12 months?
Advanced Enzyme Technologies Ltd lowest stock price was ₹251.90 and its highest was ₹366.55 in the past 12 months.
What is Advanced Enzyme Technologies Ltd’s market cap?
Advanced Enzyme Technologies Ltd’s market cap is ₹30.55B.
When is Advanced Enzyme Technologies Ltd’s upcoming earnings report date?
Advanced Enzyme Technologies Ltd’s upcoming earnings report date is May 14, 2026 which is in 39 days.
How were Advanced Enzyme Technologies Ltd’s earnings last quarter?
Advanced Enzyme Technologies Ltd released its earnings results on Jan 31, 2026. The company reported ₹2.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.8.
Is Advanced Enzyme Technologies Ltd overvalued?
According to Wall Street analysts Advanced Enzyme Technologies Ltd’s price is currently Overvalued.
Does Advanced Enzyme Technologies Ltd pay dividends?
Advanced Enzyme Technologies Ltd pays a Quarterly dividend of ₹1.2 which represents an annual dividend yield of 1.7%. See more information on Advanced Enzyme Technologies Ltd dividends here
What is Advanced Enzyme Technologies Ltd’s EPS estimate?
Advanced Enzyme Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advanced Enzyme Technologies Ltd have?
Advanced Enzyme Technologies Ltd has 111,926,800 shares outstanding.
What happened to Advanced Enzyme Technologies Ltd’s price movement after its last earnings report?
Advanced Enzyme Technologies Ltd reported an EPS of ₹2.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.825%.
Which hedge fund is a major shareholder of Advanced Enzyme Technologies Ltd?
Currently, no hedge funds are holding shares in IN:ADVENZYMES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing, and malting, and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications. It also provides non-food processing enzymes for textile processing, leather, pulp and paper, detergents and cleaning aids, bio-fuels, and biocatalysis. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Gufic Biosciences Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―